Cheng-Hao Chuang

14PUBLICATIONS
19CO-AUTHORS
Molecular targetsPredictive and prognostic markersAir pollution modelling and controlApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jun 19, 2026
Local consolidative therapy after EGFR-TKI response in advanced EGFR-mutant NSCLC.

|Sep 26, 2025
Clinical Outcomes of Different Generation EGFR TKIs in Susceptible EGFR-Mutated Advanced Nonsmall-Cell Lung Cancer.

Chia-Yu Kuo, Tien-Chi Huang, Chih-Jen Yang

|Jun 17, 2025
Impact of Spread Through Air Spaces (STAS) on Recurrence and Surgical Trends in Stage I Non-Small Cell Lung Cancer: A Real-World Cohort Study.

Cheng-Hao Chuang, Yu-Wei Liu, Wei-An Lai

|Nov 27, 2024
Changes in Staging and Management of Non-Small Cell Lung Cancer (NSCLC) Patients Following the Implementation of Low-Dose Chest Computed Tomography (LDCT) Screening at Kaohsiung Medical University Hospital.

Chin-Ling Chen, Jui-Sheng Hsu, Yi-Wen Shen

|Mar 25, 2024
Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung.

Chia-Yu Kuo, Ming-Ju Tsai, Jen-Yu Hung

|Apr 13, 2023
Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib.

Ming-Ju Tsai, Jen-Yu Hung, Juei-Yang Ma

Pageof 3

Frequent Collaborators

12 joint publications

Jen-Yu Hung

7 joint publications

Inn-Wen Chong

6 joint publications

Kuan-Li Wu

5 joint publications

Yu-Kang Tu